Payment overview · 2025
General Payments
$33,867.59
79 reported records · 17 companies
Healthcare provider profile · identity verified
Stacey L Epps, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CHESTER, VA · NPI 1154391571
Verified facts
What the public records show
CMS Open Payments records show Stacey L Epps, M.D. received $33,867.59 in general payments during 2025 across 79 reported records.
Lilly USA, LLC accounted for 60.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Nayzilam, Valtoco, Vumerity, Zeposia.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zeposia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 976 records involving 466 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zeposia by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Valtoco by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20,488.09 | 60.5% | 24 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $12,299.85 | 36.3% | 21 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $249.48 | 0.7% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $191.03 | 0.6% | 13 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $134.43 | 0.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $119.70 | 0.3% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $70.45 | 0.2% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$67.92 | 0.2% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $57.50 | 0.2% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $33.99 | 0.1% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$29.83 | 0.1% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $28.03 | 0.1% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $24.06 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.87 | 0.1% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $17.75 | 0.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$17.31 | 0.1% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $16.30 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,800.00 | 14 |
| Compensation for serving as faculty or as a speaker for a medical education program | $9,537.50 | 10 |
| Food and Beverage | $2,259.72 | 52 |
| Consulting Fee | $1,545.00 | 2 |
| Travel and Lodging | $725.37 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20,488.09 | 24 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $12,333.66 | 23 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $283.47 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $134.43 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $84.87 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $78.81 | 7 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $74.06 | 4 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $67.92 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $57.50 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $27.35 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 133 | exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 15 | exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 976 supporting records · 466 recipient NPIs · example record 1184381876 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
148 | 16 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
133 | 18 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
15 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 657 | 208 |
| Memantine Hcl | Memantine Hcl | 654 | 193 |
| Levetiracetam | Levetiracetam | 371 | 77 |
| Topiramate | Topiramate | 327 | 75 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 300 | 87 |
| Gabapentin | Gabapentin | 204 | 63 |
| Primidone | Primidone | 197 | 53 |
| Lacosamide | Lacosamide | 180 | 30 |
| Xcopri | Cenobamate | 148 | 16 |
| Briviact | Brivaracetam | 133 | 18 |
| Oxcarbazepine | Oxcarbazepine | 123 | 19 |
| Lamotrigine | Lamotrigine | 120 | 26 |
| Pregabalin | Pregabalin | 116 | 34 |
| Divalproex Sodium | Divalproex Sodium | 110 | 18 |
| Carbamazepine Er | Carbamazepine | 84 | suppressed |
| Phenobarbital | Phenobarbital | 82 | 14 |
| Aimovig Autoinjector | Erenumab-Aooe | 81 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 20 |
| Divalproex Sodium Er | Divalproex Sodium | 70 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 16 |
| Dalfampridine Er | Dalfampridine | 64 | suppressed |
| Clonazepam | Clonazepam | 63 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 62 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 62 | 15 |
| Memantine Hcl Er | Memantine Hcl | 57 | 16 |
| Levetiracetam Er | Levetiracetam | 55 | 13 |
| Rytary | Carbidopa/Levodopa | 49 | suppressed |
| Risperidone | Risperidone | 48 | 16 |
| Carbamazepine | Carbamazepine | 47 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 11 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 12 |
| Diazepam | Diazepam | 38 | 24 |
| Baclofen | Baclofen | 37 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 37 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 36 | suppressed |
| Fycompa | Perampanel | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Ubrelvy | Ubrogepant | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 32 | suppressed |
| Clobazam | Clobazam | 32 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 32 | suppressed |
| Lamotrigine Er | Lamotrigine | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Teriflunomide | Teriflunomide | 27 | suppressed |
| Lamictal | Lamotrigine | 26 | suppressed |
| Tegretol Xr | Carbamazepine | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Entacapone | Entacapone | 24 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 24 | suppressed |
| Depakote | Divalproex Sodium | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Valtoco | Diazepam | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Trokendi Xr | Topiramate | 16 | suppressed |
| Vimpat | Lacosamide | 16 | suppressed |
| Nayzilam | Midazolam | 15 | 12 |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Vumerity | Diroximel Fumarate | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33,867.59 · 79 records | Lilly USA, LLC | AMYVID, Briviact, Fintepla, Gocovri, KISUNLA, LEQEMBI, Nayzilam, PERCEPT PC BRAINSENSE, PRECIVITYAD2, TYSABRI, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, ZEPOSIA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error